Caspase-3 Is Transiently Activated without Cell Death during Early Antigen Driven Expansion of CD8+ T Cells In Vivo by McComb, Scott et al.
Caspase-3 Is Transiently Activated without Cell Death
during Early Antigen Driven Expansion of CD8
+ T Cells In
Vivo
Scott McComb, Rebecca Mulligan, Subash Sad*
NRC-Institute for Biological Sciences, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
Abstract
Background: CD8
+ T cell responses develop rapidly during infection and are swiftly reduced during contraction, wherein
.90% of primed CD8
+ T cells are eliminated. The role of apoptotic mechanisms in controlling this rapid proliferation and
contraction of CD8
+ T cells remains unclear. Surprisingly, evidence has shown non-apoptotic activation of caspase-3 to
occur during in vitro T-cell proliferation, but the relevance of these mechanisms to in vivo CD8
+ T cell responses has yet to
be examined.
Methods and Findings: We have evaluated the activity of caspase-3, a key downstream inducer of apoptosis, throughout
the entirety of a CD8
+ T cell response. We utilized two infection models that differ in the intensity, onset and duration of
antigen-presentation and inflammation. Expression of cleaved caspase-3 in antigen specific CD8
+ T cells was coupled to the
timing and strength of antigen presentation in lymphoid organs. We also observed coordinated activation of additional
canonical apoptotic markers, including phosphatidylserine exposure. Limiting dilution analysis directly showed that in the
presence of IL7, very little cell death occurred in both caspase-3
hi and caspase-3
low CD8
+ T cells. The expression of active
caspase-3 peaked before effector phenotype (CD62L
low) CD8
+ T cells emerged, and was undetectable in effector-phenotype
cells. In addition, OVA-specific CD8
+ cells remained active caspase-3
low throughout the contraction phase.
Conclusions: Our results specifically implicate antigen and not inflammation in driving activation of apoptotic mechanisms
without cell death in proliferating CD8
+ T cells. Furthermore, the contraction of CD8
+ T cell response following expansion is
likely not mediated by the key downstream apoptosis inducer, caspase-3.
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Introduction
Antigen presenting cells (APC) activate rare antigen specific
CD8
+ T cells, and induce their clonal expansion (up to 10,000
fold) within 7 days [1]. Rapid expansion is usually followed by a
contraction phase wherein ,95% of the primed cells are
diminished from primary lymphoid tissue [2,3]. Programmed
mechanisms of cell death (apoptosis) would seem to be an obvious
fit in the role of eliminating antigen specific cells during
contraction [4]. Indeed, death receptors, signaling mechanisms,
and pro-apoptotic mediators have been implicated in the removal
of activated cells after an immune response [5–8]. Conversely,
studies examining the importance of apoptotic mechanisms in the
immune response have also revealed that apoptotic mediators can
be associated with T cell activation, but not death in some in vitro
models [9,10].
The complex roles of apoptotic mechanisms in the T cell
response are exemplified by the function of the Fas receptor. While
mutation of the Fas receptor or its ligand leads to serious
lymphoproliferative disorders in both mouse and human [11], the
mutation of Fas or loss of its signaling proteins (eg FADD or
caspase-8) also results in perplexing defects in antigen induced T
cell proliferation [12–15]. The importance of caspases in T cell
activation is reiterated by defective T cell activation observed in
humans lacking functional caspase-8 [16]. Furthermore, chemical
inhibitors of caspases have been shown to inhibit T cell activation
[17].
More generally, a paradoxical connection between apoptotic
mechanisms and cell proliferation is rapidly gaining acceptance
[10,18,19]. Similarly to caspase-3, it has been observed that
another classical marker for apoptosis, phosphatidylserine (PS)
exposure, can occur in proliferating CD8
+ T cells [20]. The
programmed death marker (PD-1) has also been shown to be
upregulated during CD8
+ T cell activation. Despite the mounting
evidence for a role of apoptotic mechanisms in T cell proliferation,
little work has been done to investigate their activation during an
in vivo T cell response. In addition, the possibility that significant
cell death is occurring in parallel with expansion has not been
examined. It also remains unclear whether these mechanisms are
induced during the contraction phase of the CD8
+ T cell response.
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of the CD8
+ T cell response, insight can be gained into the link
between the signaling networks of immune stimulation and cell
death. In this report, we have used an antibody and a fluorogenic
substrate which specifically detect active caspase-3 to analyze the
level of active caspase-3 in antigen specific CD8
+ T cells
throughout the in vivo response. We also examine the level of PS
exposure and PD-1 expression. We have tracked these markers in
OVA specific CD8
+ T cells as they respond to a common antigen,
expressed by two divergent pathogens. CD8
+ T cell response to
the highly immunogenic bacterial pathogen Listeria monocytogenes
expressing OVA (LM-OVA) was compared with poorly immuno-
genic, Salmonella typhimurium, also expressing OVA (ST-OVA).
By simultaneously examining the levels of apoptotic and T cell
activation markers, we reveal that antigen-presentation, but not
inflammation, induces actively proliferating CD8
+ T cells to take
on an apoptotic like phenotype without cell death. Thus, our
results support a model in which caspase-3 is induced by antigenic
stimulation and acts atypically during CD8
+ T cell proliferation.
Furthermore, because active caspase-3 remained low throughout
contraction, this indicates that the removal of antigen specific
CD8
+ T cells following a response occurs through caspase-3
independent mechanisms.
Results
Active Caspase-3 is up-regulated during T cell activation
in vitro
OVA-specific CD8
+ TCR transgenic mouse (OT-1) splenocytes
were placed in culture with various concentrations of OVA
peptide (SIINFEKL). OVA specific CD8
+ T cells began
proliferating within 24 hours of initial stimulation. Intracellular
staining was performed using fluorescently labeled antibodies.
Those OT-1 CD8
+ T cells that were stimulated with an amount of
antigen greater then about 0.1 nM (10
24 mg/ml) showed active
proliferation, as identified by high expression of the active cell
cycle marker Ki67 (Fig. 1A). The proliferative capacity of these
cells was further confirmed by the loss of CFSE staining after
activation (Fig. 1B). Coordinated with an increase in proliferation,
we observed a significant increase in the level of active caspase-3 in
the CD8
+ population as the antigen levels increased from 10
28 to
10
22 mg/ml (P,0.005, Fig. 1). Co-staining revealed direct
correlation between caspase-3 cleavage and cell proliferation
(Ki67
hi) within the CD8
+ population (Fig 1D).
Activated CD8
+ T cells remain viable despite high
expression of active Caspase-3
To investigate whether caspase-3 activation is leading to cell
death, we next examined the viability of OVA stimulated cells in
vitro. The viability of proliferating CD8
+ cells was directly assessed
by terminal dUTP nick end labeling (TUNEL) for DNA cleavage.
In the absence of any peptide stimulation or growth factors, cells
became TUNEL
+ at later time periods indicating progression to
death (Fig. 1C). Stimulation of cells with OVA-peptide resulted in
significant reductionof the overalllevel of DNAcleavage,indicating
that stimulated cells were not progressing to apoptotic cell death.
Despite the high level of active caspase-3 present in actively
proliferatingcells therewaslittleindicationof increasedcell death as
determined by TUNEL staining (Fig. 1C). This shows a surprising
inverse correlation between the level of active caspase-3 and DNA
cleavage as antigenic stimulation of the CD8
+ T cells increases.
The reduced overall TUNEL staining in in vitro activated cultures
does not preclude the possibility that a significant level of cell death
is occurring in caspase-3
hi cells, with a concurrent vigorous
outgrowth of active caspase-3
low cells. To address this, OT1 spleen
cells were activated in vitro with LM-OVA. After 18 h, bacteria were
removed by gentamicin treatment and OT-1 cells (very low
numbers) cultured with addition of cytokine, IL-7. The data
indicate that proliferating caspase 3
hi CD8
+ T cells do not progress
to cell death (Figure S1). Cells were seeded at such low numbers in
order to avoid the statistical probability that a small proliferative
subpopulation of cells could account for the majority of the culture
while significant cell death is occurring in the majority of cells.
To further confirm cell viability, cells were co-stained directly for
CD8, active caspase-3 and DNA cleavage. OT-1 cells were first left
un-stimulated, stimulated with OVA-peptide, or with staurosporine
(inducer of apoptosis). After 2 days in culture, cells were plated,
stained, and examined by fluorescent microscopy. Un-stimulated
CD8
+ T cells showed minimal active caspase-3 expression (Fig. 2),
while those treated with staurosporine showed elevated active
caspase-3 expression. In the staurosporine treated cells, active
caspase-3 was associated with TUNEL in approximately half of
active caspase-3 positive cells. In contrast to unstimulated or
apoptotic cells, antigen stimulated OT-1 cells grew significantly in
size and showed elevated active caspase-3 expression without a
significant number of TUNEL
+ cells (Fig. 2). We observe
approximately 5% of cells which showed active caspase-3 to also
be positive for TUNEL staining. Cells that were found to be
TUNEL
+/caspase-3
+ in the OVA-peptide stimulated cultures did
not appear to have CD8 expression. Therefore, these results further
confirm that caspase-3 is induced during T cell activation, but
caspase3
hi cells do not progress rapidly to cell death.
Upregulation of Caspase-3 occurs during early activation
of CD8
+ T cells in vivo
We next evaluated the temporal expression of active caspase-3
during CD8
+ T cell activation in vivo. OVA-specific CD8
+ T cells
were also examined for a range of cell markers, associated with
apoptosis and activation, throughout the course of the immune
response. At day 3 of LM-OVA infection, .80% of OVA specific
CD8
+ T cells showed highly elevated active caspase-3 expression
(Fig. 3A, E). The percentage of OVA-specific CD8
+ T cells
expressing active caspase-3 decreased progressively as responding
cells approached the peak of response at day 7 post-infection and
remained at a basal level subsequently. Increased caspase-3
activity was confirmed by staining cells with the fluorogenic
caspase-3 substrate PhiPhiLux (PPL), which showed similar results
(Fig. 3B, F). Cells consistently showed basal levels of active
caspase-3 beyond day 40. In addition, upon re-challenge with LM-
OVA, OVA-specific CD8
+ T cells showed rapid and highly
transient caspase-3 activation, consistent with secondary expansion
of a memory population (data not shown).
Transfer of high numbers of TCR transgenic cells into hosts has
been shown to hasten the onset of contraction [21]. To avoid this,
we have used small numbers of OT-1 transgenic cells in our
adoptive transfer model, which does not alter the programming or
contraction of OVA-specific CD8
+ T cells significantly. Even
without adoptive transfer of OT1 cells, proliferating OVA-specific
CD8
+ T cells expressed high levels of caspase 3, which was absent
during the contraction phase (Figure S2).
Active Caspase-3 is accompanied by moderate
upregulation of other apoptotic markers
We next evaluated other common markers of apoptosis.
Phosphatidylserine (PS) is normally only exposed on the surface
of apoptotic cells [22]. Thus, we measured PS exposure using
fluorescent annexin V. The upregulation of caspase-3 was
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be noted that when apoptosis was induced by staurosporine, the
level of annexin V binding (MFI) in activated cells was determined
to be higher than that observed in the proliferating cells (data not
shown). At day 3 post-infection the majority of antigen specific
CD8
+ T cells showed that PS externalization increased to an
intermediate level, which fell rapidly to basal levels by the peak of
the CD8
+ T cell response at day 7. Programmed death receptor 1
(PD-1) was originally identified as an early marker for cell death
[23], thus we also examined its correlation with active caspase-3
during CD8
+ activation. As with caspase-3 and annexin V
binding, OVA-specific CD8
+ T cells expressed high levels of
PD-1 early on, and by day 7 the expression of PD-1 was at basal
levels (Fig. 3D, H). Finally, we noted direct correlation between
Ki-67 versus caspase-3 expression in vivo (Fig. 4A). Collectively,
these results indicate that activated OVA specific CD8
+ T cells
have an apoptotic-like phenotype during their early expansion
phase, while the cell number continues to increase. However, by
the time the numbers of OVA-specific CD8
+ T cells peak and
contraction begins, the expression of these apoptotic mediators is
reduced to baseline levels.
Cells with elevated caspase-3 expression do not progress
to cell death in vivo
The apparent apoptotic phenotype observed in actively
proliferating CD8
+ T cells in vivo required a careful assessment
of their viability. Firstly, we examined cell viability directly at
Figure 1. Significant increase in active caspase-3 during T cell activation correlates directly with an increase in proliferation. A single
cell suspension of OT1 splenocytes, some of which were first CFSE stained, were placed in culture with varying concentrations of SIINFEKL peptide for
48 hours and analyzed by intracellular flow cytometry (n$3). Cells were stained with anti-CD8 antibody and OVA-tetramer, then fixed and
permeabilized before staining with anti- active caspase-3 antibody and Ki67. Graphs show the mean fluorescence intensity (MFI) of CD8
+ OVA-
tetramer
+ gated cells. (A) MFI of active caspase-3 versus Ki67 show a high amount of linear correlation in their expression levels (P,0.05). There is a
significant increase in the expression of both caspase-3 and Ki67 from 10
28 to 10
22 mg/mL OVA (P,0.005). (B) MFI of CFSE versus active caspase-3,
inverse correlation was found to be significant (P,0.01). (C) MFI of TUNEL stain versus active caspase-3, inverse correlation was found to be
significant (P,0.01). (D) Scatterplots show the relative expression of active caspase-3 versus Ki67 for gated CD8
+ cells in splenocyte cultures treated
for 48 hours with varying amounts of SIINFEKL peptide as shown. Data shown is representative for two repeated experiments performed in triplicate.
doi:10.1371/journal.pone.0015328.g001
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deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
and active caspase-3 co-staining in antigen specific cells (Fig. 4B).
We observed a minimal increase in TUNEL staining associated
with active caspase-3 upregulation early in CD8
+ T-cell response
(day 3). It should be noted that some level of increased TUNEL
staining can be associated with proliferating cells. We also allowed
up to 24 hours ex vivo for possible cell death and DNA cleavage to
proceed before TUNEL staining, and observed similar results
(Figure S3).
The lack of terminal cell death in vivo may be alternatively
explained by the rapid clearance of dead cells by macrophages,
thus we used the fluorogenic caspase-3 substrate PhiPhiLux to
purify OVA-specific CD8
+ T-cells at day 5 of infection into active
caspase-3
hi and caspase-3
low fractions (Fig. 5A). In order to
examine their viability directly over several days we utilized
TMRE staining for mitochondrial activity (Fig. 5B, C). In the
presence of the supportive cytokine (IL-7), active caspase-3
hi cells
were able to persist and proliferate with a low level of concurrent
cell death similar to active caspase-3
low cells. Conversely, when
cells were placed in media without IL-7, both active caspase-3
hi
and caspase-3
low cells died rapidly, underlining the necessity for
IL-7 in proliferating CD8
+ cell populations [24]. The viability of
both caspase-3
hi and caspase-3
low populations was also confirmed
by TUNEL staining at day 1 in culture (Fig. 5D). It should be
noted that IL-7 did not inhibit apoptosis of CD8
+ T cells induced
by staurosporine (Figure S4.). Cells were seeded at very low
numbers (12.5 cells/well) in order to avoid the statistical possibility
that a minor subpopulation can completely overtake dying
caspase3
hi cells. A hypothetical 10% contaminant subpopulation
in the sorted caspase3
hi population would have to proliferate more
than 50-fold (,5.5 clonal divisions) in 24 h to overtake the culture
completely; a highly unlikely scenario given the calculated rates of
division of CD8
+ T cells during their peak proliferative phase (,3
divisions) [3,25]. Rather, this data indicates that the induction of
active caspase-3 associated with antigen induced proliferation of
CD8
+ T cells in vivo does not lead to significant cell death.
Differentiated effector phenotype cells express basal
levels of active caspase-3
Next, we wanted to assess more precisely when and how
caspase-3 is up-regulated relative to T cell activation and
proliferation. CD62L and IL-7Ra expression can be used to
differentiate between naı ¨ve and differentiated effector CD8
+ T
cells, as well as the type of memory cells produced. Thus, we co-
stained cells for CD62L, IL-7Ra and active caspase-3 over several
time points. As naı ¨ve CD8
+ T cells underwent differentiation, they
initially showed high expression of active caspase-3, but few cells
displayed an effector (CD62L
low IL-7Ra
low) phenotype (Fig. 6A,
B). At the peak of caspase-3 expression (day 3), CD62L expression
had decreased only modestly. Subsequently, the expression of both
active caspase-3 and CD62L decreased precipitously. At day 7,
when the primed CD8
+ T cells displayed mainly effector
(CD62L
low) phenotype, cells also expressed basal level of
Figure 2. Active caspase-3 in antigen activated T cells is expressed in live proliferating cells. OT1 spleen cells were stimulated in vitro for
48 hours with varying amounts of antigen. Apoptotic control cells were treated with 1 mg/ml staurospaurine. Cells were then stained with anti-CD8
antibody and fixed and permeabilized before TUNEL and caspase-3 staining. Cells were mounted on slides and examinated by fluorescence
microscopy. Images show TUNEL staining (green), and active caspase-3 (red) in CD8 labeled T cells (blue). The images are representative of 3 repeated
examinations for each differentially stimulated culture. Arrows shown identify cells with positive staining for both caspase-3 and TUNEL.
doi:10.1371/journal.pone.0015328.g002
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showed low levels of active caspase-3. Thus, the timing of elevated
caspase-3 activity matches the timing of CD8
+ T cell proliferation,
and precedes their differentiation to a primarily effector
population.
To directly examine the mode of caspase-3 activation relative to
their proliferation and differentiation, mice were concurrently
injected with CFSE stained OT-1 CD8
+ T cells and LM-OVA.
This allowed the direct observation of proliferation versus the
expression of active caspase-3 and differentiation markers at a
single time point. Cells that had undergone only a few rounds of
division expressed the highest levels of caspase-3, and this was
progressively lost as the cells underwent further rounds of division
and effector phenotype cells emerged (Fig. 7A, B). These results
further support a model wherein caspase-3 is upregulated
transiently during the proliferation of recently activated CD8
+ T
cells, and this apoptotic-like phenotype is progressively lost as cells
proliferate further, and differentiated effector cells emerge.
Caspase-3 activation occurs in lymphoid tissue
CD8
+ T cell activation and proliferation occurs mainly within
secondary lymphoid tissue such as spleen. Non-lymphoid tissue,
such as lungs, can be exposed to numerous infectious agents that
may influence the apoptotic phenotype, or caspase-3 expression in
antigen-specific CD8
+ T cells. We thus characterized the tissue
localization of active caspase-3 during the response to LM-OVA.
Splenic OVA specific CD8
+ T cells showed elevated active
caspase-3 at day 4 after LM-OVA infection. In contrast, active
caspase-3 was minimally expressed in OVA-specific CD8
+ T cells
isolated from peripheral blood, lungs or brain (Fig. 8). A basal level
of caspase-3 activity was observed in all tissues at day 7 after
response. Thus the activation of CD8
+ T cells drives the
upregulation of active caspase-3, primarily within lymphatic tissue.
Furthermore, differentiated effector cells that move into the
periphery have only basal caspase-3 levels.
Caspase-3 activation is determined by timing and
strength of antigen-presentation
While the LM-OVA model showed a clear correlation between
the timing of early CD8
+ T cell activation and upregulation of
caspase-3 activity, we were interested in determining the
expression of caspase-3 during another infection model that
differed in the degree and timing of antigen-presentation. We have
previously shown that antigen-presentation is highly muted and
delayed during infection of mice with ST-OVA, resulting in the
development of a CD8
+ T cell response that peaks ,day 20 [26–
28]. Using OT-1 adoptive transfer and ST-OVA infection, we
observed delayed and reduced induction of active caspase-3
coordinate with delayed and lower OVA-specific CD8
+ expansion,
Figure 3. Rapidly proliferating CD8
+ T cells have an apoptotic like phenotype in vivo. C57BL6/J mice were injected with 10
4 OT1 cells and
infected with 10
4 LM-OVA. At various time points mice were sacrificed and splenic cells were stained and analyzed by FACS. Scatterplots show OVA-
tetramer binding versus (A) active caspase, (B) PhiPhiLux cleavage by caspase-3 (PPL), (C) Annexin V binding and (d) PD-1, in cells over days 3, 4 and 7
of LM-OVA infection. The % of OVA-tetramer
+ CD8
+ cells expressing a high level of (Em) caspase-3, (FN) PPL cleavage, (G D) Annexin V binding, and (H
#) PD-1 are shown over the course of an acute OVA specific CD8
+ T cell response (&). *The decrease in apoptotic staining between day 3 and 7
shows significant linear correlation (by Pearson analysis) between active caspase-3 antibody staining and (E) PPL cleavage activity, (F) annexin V
binding and (G) PD-1 expression (P,0.05). **Change in active caspase-3 staining is inversely proportional to an increase in OVA-tetramer specific cells
(P,0.001, n= 3 mice/timepoint).
doi:10.1371/journal.pone.0015328.g003
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caspase-3 activation corresponded directly with the timing of
elevated Ki67, PD1 and CD62L expression. At around day 25–30
post infection (peak of response), cells maintained only a basal level
of active caspase-3 and Ki67. During ST-OVA infection, the
majority of primed cells display a prolonged effector/effector
memory phenotype [26,27,29] as revealed by persistently low
CD62L expression (Fig. 9A). However, similar to LM-OVA
infection, the expression of active caspase-3 was not maintained on
effector CD8
+ T cells. Taken together, in both LM-OVA and ST-
OVA infection models, caspase-3 was induced during the phase of
active CD8
+ T cell proliferation. Furthermore, active caspase-3
remained at basal levels as CD8
+ T cell responses peaked and
effector phenotype cells emerged. TUNEL data again indicates
that the observed changes in the level of active caspase-3 do not
correlate with significant cell death (Fig 9B).
Caspase-3 cleavage is driven primarily by antigen in vivo
We next evaluated the relative influence of antigen versus
inflammation on the induction of caspase-3 in CD8
+ T cells in vivo.
To address this, we resorted to comparing the two infection
models, LM-OVA and ST-OVA and their relative timing and
strength of active caspase-3 induction. Firstly, we measured the
bacterial burden during the first seven days of infection. LM-OVA
was rapidly cleared after the first few days of infection, whereas
ST-OVA burden continued to increase over the seven day period
(Fig. 10A). We also examined the relative level of OVA mRNA by
qRT-PCR during infection of mice with LM-OVA and ST-OVA.
While the spleens of mice infected with LM-OVA showed a
significant peak in OVA transcription at day 3 post-infection,
spleens of ST-OVA infected mice showed very little OVA mRNA
by day 7 post-infection (Fig. 10B). This result explains why the
CD8
+ T cell response is delayed during infection of mice with ST-
OVA [28], and links the timing of caspase-3 cleavage to the timing
of antigen presentation. Next, we used a cytokine array to measure
the expression of 40 cytokines/chemokines simultaneously in the
spleens of LM-OVA and ST-OVA infected mice at day 6 post-
infection. ST-OVA infection resulted in much higher expression of
inflammatory cytokines/chemokines relative to LM-OVA
(Fig. 10C). Taken together these data indicate LM-OVA infection
induces more antigen load and more caspase-3 activation, whereas
during ST-OVA infection, poor antigen load but higher
inflammation fails to drive the upregulation of caspase-3 early on.
We also injected CFSE labeled OT-1 cells concurrently with
LM-OVA and ST-OVA infection, and evaluated the proliferation
of transferred OT-1 cells after 5 days in vivo. The majority of OT-1
cells in LM-OVA infected mice had reduced CFSE expression and
higher levels of active caspase-3 (Fig. 10D), whereas OT-1 cells in
ST-OVA infected mice remained mainly CFSE
hi and caspase3
low.
Thus, ST-OVA infection which induces massive inflammation,
but little antigen expression results in poor cycling of CD8
+ T cells,
and does not influence caspase-3 expression in CD8
+ T cells
during the first week of infection. We also examined the effects of
antigen versus inflammatory stimulation on active caspase-3
expression and cell cycling in vitro. While antigen stimulation can
simultaneously increase cell proliferation (Ki67
hi) and active
caspase-3 expression, inflammatory stimulation in the form of
heat killed bacteria (LM or ST) has little effect on caspase-3
expression in stimulated or unstimulated cultures (Figure S5).
Taken together, these results indicate that antigen is the principal
inducer of caspase-3 cleavage in CD8
+ T cells.
Caspase-3 is not activated during homeostatic
proliferation
Having noted that antigen stimulated proliferating CD8
+ T cells
express caspase-3, we determined whether non-antigen induced
homeostatic CD8
+ T cells proliferation is also associated with
caspase-3 activation. The transfer of OT-1 CD8
+ T cells to
lymphopenic hosts (Rag1-deficient recipient mice) results in a
relatively rapid proliferation of transferred CD8
+ T cells in the
Figure 4. Actively proliferating cells in vivo co-express markers for apoptosis and proliferation with little apparent cell death. C57BL/
6 mice were parked with 10
4 OT1 cells and challenged with 10
4 LM-OVA. Splenic cells were obtained from infected C57BL/6 mice at various time
points after infection and stained for CD8 and OVA-tatramer binding as well (A) proliferation marker Ki67 vs. active caspase-3. (B) Cells were also co-
stained for DNA cleavage (TUNEL) vs. active caspase-3 expression.
doi:10.1371/journal.pone.0015328.g004
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5 CFSE stained OT-1 CD8
+
T cells to WT and Rag1-deficient mice. Groups of WT mice were
also challenged with LM or LM-OVA. Spleens were removed at
day 5 post-infection and cells were stained to evaluate the donor
CD8 population and the expression of active caspase-3. In Rag-1-
deficient hosts, transferred CD8
+ T cells had undergone significant
homeostatic proliferation as revealed by CFSE dilution, however,
there was no apparent upregulation of caspase-3 activity (Fig. 11).
Conversely, in the WT mice, only those mice challenged with LM-
OVA showed proliferation associated with significant activation of
caspase-3. Wild-type LM (without OVA) induced low level non-
specific proliferation of transferred cells but failed to induce the
expression of caspase-3 on OVA-specific CD8
+ T cells. These
results further indicate that caspase 3 is specifically induced by
antigen presentation and not upregulated during non-specific or
homeostatic proliferation.
Discussion
CD8
+ T cell responses can provide effective pathogen clearance,
as well as long-term protection against pathogens due to their
ability to develop into memory cells, however, the mechanisms
that govern the highly dynamic processes of proliferation,
contraction and memory formation are unclear [3]. In particular,
the role of apoptotic mechanisms in proliferation [9,10] and
contraction [30] of primed CD8
+ T cells remains elusive. Caspase-
3 cleavage is often referred to as the key downstream apoptotic
event, and can be activated by a variety of pathways including
death receptor driven caspase-8 cleavage, or mitochondrial driven
caspase-9 cleavage [31]. In this study we have used two divergent
infection models to evaluate the influence of antigen and
inflammation on the timing and duration of caspase-3 activation
in antigen-specific CD8
+ T cells during their proliferation,
differentiation and contraction.
Our data clearly shows that caspase-3 is activated following
antigen specific stimulation of CD8
+ T cells. This adds to previous
findings showing specific induction of caspase-3 mRNA following
TCR stimulation [32]. An important question that remains is how
caspase-3 cleavage might be induced following TCR engagement?
Work in photoreceptors has shown that elevated intracellular
calcium can activate calpains that in turn cleave caspase-3 [33].
Calpains lyse particular protein targets and have been proposed to
stimulate the mitochondrial release of cytochrome C and
activation of caspase-9 [34]. Similarly, high level calcium signaling
associated with TCR stimulation [35] may lead to caspase-3
activation during CD8
+ T cell stimulation.
It has recently been shown that caspase-3 activation occurs in T
cells under anergizing conditions. Caspase-3 was shown to drive
Figure 5. The majority of active caspase-3
hi cells do not progress to cell death during early antigen induced proliferation in vivo.
Mice were parked with 10
4 CD45.1
+ OT1 spleen cells and challenged with 10
4 LM-OVA (iv). Mice were sacrificed at day 5 post LM-OVA infection and
CD8
+ T cells were magnetically isolated by negative selection. Cells were stained with anti-CD45.1 antibody and PhiPhiLux. (A) Cells were sorted into
CD45.1
+ caspase-3 activity high and CD45.1
+ caspase-3 activity low fractions. (B) Sorted cells were then plated at low cell densities (,12.5 cells/well)
and examined for viability during proliferation over several days using TMRE staining. (C) The total number and number of dead cells were counted
directly in at least 6 replicate wells and the changes observed over 72 hours in the plates. (D) Cells were also maintained at higher concentrations
(,100 000/well) and stained for DNA cleavage (TUNEL) after 1 day in culture.
doi:10.1371/journal.pone.0015328.g005
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[36], and the downregulation of CD28 expression [37]. These
results were obtained with T cell lines stimulated in vitro and it was
not clear whether caspase-3 activation was also associated with
normal CD8
+ T cell activation. In contrast, our results (in vitro and
in vivo) indicate that caspase-3 activation occurs during the
‘normal’ antigen specific activation of T cells. Indeed, active
caspase-3 was consistently and directly associated with rapidly
proliferating (Ki-67
+) CD8
+ T cells.
In a mouse model of Lymphocytic choriomeningitis virus (LCMV)
infection wherein caspase-3 was also observed to be elevated
during proliferative phases, it was suggested that pro-apoptotic
mediators may function to degrade anti-apoptotic mediators and
prepare cells for delayed apoptosis [38]. However, a critical
question that remained was why the levels of downstream
apoptotic mediators dropped to background levels before the
onset of contraction. In addition, while short-lived effector cells
(SLEC) that emerge at the peak of CD8
+ T cell response (day 7)
against LCMV express KLRG1 [39], we do not observe a strong
correlation between active caspase-3 and KLRG1 expression in
LM-OVA infection (data not shown). Thus, caspase-3 activation
occurs transiently during the rapid phase of proliferation and does
not appear to influence the differentiation of CD8
+ cells to
memory or effector phenotypes.
While early inflammation is an important determinant of CD8
+
T cell contraction [30,40], no key mechanisms have come to light
that might explain the massive and rapid contraction of CD8
+ T
cell response after priming. Contraction proceeds normally in
various hosts that are deficient in key apoptotic mechanisms
[3,41–43]. The death of staphylococcal enterotoxin B (SEB)
Figure 6. The activation of caspase-3 occurs in early activated cells before the emergence of fully differentiated effector cells.
C57BL/6 mice were initially parked with 10
4 OT1 spleen cells. After infection with 10
4 LM-OVA, mice were sacrificed at various time points and spleens
were harvested. Single cell suspensions were co-stained for CD8
+, OVA-Tetramer, CD62L, IL7Ra and active caspase-3. (A) Scatter plots show the
relative staining of OVA-tetramer
+ CD8
+ cells for activation markers and active caspase-3. Data is representative for at least 3 mice per time point. (B)
OVA-tetramer
+ CD8
+ T cells were examined for active intracellular active caspase-3 and surface CD62L between days 0–15 of LM-OVA infection. (data
is representative for 3 mice per timepoint).
doi:10.1371/journal.pone.0015328.g006
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family member, Bim [44]. In the LCMV infection model,
contraction of CD8
+ T cell response was shown to be reduced,
but not absent in Bim-deficient mice [7]. The precise evaluation of
the extent of contraction is also complicated by the massive
trafficking of CD8
+ T cells to numerous non-lymphoid organs
[45]. Our results indicate that by day 7 of LM-OVA infection,
when effector-phenotype cells begin to contract, they express little
of the apoptotic markers we examined. In agreement with this, it
has previously been shown that the application of a caspase
inhibitor has no effect on contraction of CD8
+ T cell response
[46]. These findings seem to solidify the conclusion that
contraction does not occur by caspase 3 dependent apoptotic cell
death.
Despite previous evidence that activation-associated caspase-3
induction does not drive the death of cells in vitro (18, 19), the
prospect that a vigorous outgrowth of small population of caspase-
3
low cells might mask a significant level of dying caspase3
hi cells
remained a possibility. Thus, we examined proliferating cells
directly at very low cell numbers, eliminating the possibility of a
minority contaminating population being responsible for signifi-
cant outgrowth. We also confirmed these findings in vivo, where
despite the relatively high level of active caspase-3, we were unable
to detect a significant population of TUNEL
+ CD8
+ T cells. Even
purified caspase-3
hi cells did not reveal significantly elevated cell
death when compared to those cells with the lowest level of
caspase-3. We conclude that caspase-3 activation does not result in
a significant amount of cell death concurrent with CD8
+ T cell
proliferation.
Our data indicates that caspase-3 is not a determinant of CD8
+
T cell survival. In both caspase 3
hi or caspase 3
low populations on
days 4, 5 or 7 after LM-OVA infection, no significant differences
were noted in the relative death of the two populations, with both
being highly dependent on IL-7 stimulation. Indeed, expression of
IL-7 has been shown to be critical in development of CD8
+ T cell
memory [24]. It remains pertinent to ask, why would the cells
appear to go through a seemingly apoptotic program, but not
proceed to death subsequently? Differential subcellular localization
Figure 7. Caspase 3 and CD62L expression is progressively lost as proliferation proceeds. 10
4 OT1 splenocytes were stained with CFSE
and injected in C57BL/6 recipient mice concurrently with LM-OVA challenge. After 3, 4 and 5 days, mice were sacrificed (3 per time point) and spleen
cells stained for expression markers. (A) Scatterplots show expression of active caspase-3 versus CFSE and CD62L in OVA-tetramer
+ CD8
+ T cells after 4
days in vivo. (B) OVA specific CD8
+ T cells were gated for division number based on CFSE dilution. Cells show a significant, coordinate decrease in the
expression of active caspase-3 and CD62L/IL7Ra as cell proliferation proceeds (***P,0.005, *P,0.05, n=3 per timepoint).
doi:10.1371/journal.pone.0015328.g007
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+ T cells has been previously
observed, and may explain the fact that cells expressing active
caspase-3 do not proceed to cell death. Whereas it must
translocate to the nucleus during apoptosis, caspase-3 appears to
associate primarily with the cell membrane during T cell
stimulation [36]. It has also been proposed that caspase may be
more substrate selective when activated in CD8
+ T cells, perhaps
targeting proteins regulating cell cycling [47]. There may also be
an important induction of anti-apoptotic mediators in activated
CD8
+ T cells. The Birc (or IAP) proteins are classical cellular
inhibitors of caspases, which bind to the active site of caspase and
inhibit caspase activity [48]. Birc5 (survivin) has been shown to be
highly upregulated by CD28 and OX40 signaling during CD8
+
activation, and may be important in preventing caspase-3
mediated cell death [49,50].
At day 3 after LM-OVA infection, when caspase-3 expression
was at its peak, nearly all caspase-3
hi cells were also PD-1
hi and
Annexin V
hi. While the externalization of phosphatidyl serine (PS)
on the surface of cells is considered a canonical marker of cell
death, this generalization has been widely called into question.
Externalization of PS in a non-apoptotic context has been
observed after engagement of immune-receptors of mast cells, B
cells and CD8
+ T cells [20,51,52]. Similarly, PD-1 has been shown
to be a marker of recent antigenic exposure as well as exhaustion
in CD8
+ T cells [53]. The connection of PD-1 to apoptotic
mechanisms in CD8
+ T cells remains unclear [54]. While the co-
expression of canonical apoptotic mediators seems to point to
significant cell death in the activated CD8
+ T cell population, this
is inconsistent with the timing of the onset of contraction, and our
cell viability observations.
Classically, apoptotic mechanisms enact programmed cell
death, although they are increasingly being identified in roles
outside of cell death. A new paradigm regards apoptotic pathways
as complex signaling mechanisms that interact with a wide range
of cellular pathways and will not always trigger cell death, as has
been the subject of a number of recent reviews [10,55,56].
Caspase-3 cleavage specifically, has recently been shown to be vital
to the normal differentiation of skeletal muscle cells [57],
macrophages [58], erythroblasts [59], as well as others. Caspase
activity has even been observed to prevent necrotic cell death in
immortalized cell lines [60]. Similarly, regulation of cell death by
caspases may facilitate T cell viability and expansion [61]. Indeed,
the general inhibition of caspase activity has been shown to limit
the proliferation of T cells in vitro [17] (Figure S6). While, the
broad range of caspase-3 targets makes it difficult to dissect the
exact mechanisms by which caspase-3 affects the proliferation of
CD8
+ T cells, this may in fact be a key functional property in T
cell activation. The ability of apoptotic proteases, such as caspase-
3, to target many protein signaling networks [62] may make them
well suited tools to precipitate change in cellular signaling program
Figure 8. Elevated active caspase-3 is found primarily in secondary lymphoid tissues early in T cell activation. Mice parked with 10
4
OT1 cells were challenged with 10
4 LM-OVA. At various time points, mice were perfused and organs removed. Single cell suspensions were stained
and analyzed by FACS. (A) Scatterplots show OVA-tetramer binding versus active caspase-3 expression in CD8
+ T cells. Plots are representative of 3
mice analyzed. (B) The % of OVA-tetramer
+ cells in each organ (upper right) and the change in the level of active caspase-3 expression in OVA specific
CD8
+ T cells (lower right) from each organ is shown. There is a significantly higher proportion of active caspase-3 high cells in the spleen when
compared to PBL, lungs or brain at day 4 (*P,0.005, n=2 per timepoint).
doi:10.1371/journal.pone.0015328.g008
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differentiation.
Thus, using two different infection models that differ in the
relative expression of antigen versus inflammation, we have shown
that TCR signaling, and not inflammation, is the key mechanism
that drives the induction of caspase-3. Taken together these results
resolve some controversies by providing strong evidence that
active caspase-3 is: (a) directly stimulated by antigen, (b) expressed
transiently during proliferation, (c) not associated with contraction
of the response, (d) coupled with activation of other canonical
apoptotic mediators, and (e) does not lead to cell death.
Materials and Methods
Mice and infections
All animals were housed in the animal facility of the Institute for
Biological Science and maintained according to CCAC guidelines.
Protocols and procedures (Protocol #2008-10) were approved and
monitored by the National Research Council of Canada-Institute
for Biological Sciences Animal Care and Ethics Board.
C57BL/6J mice, 3–4 weeks of age were obtained from Jackson
Labs (Bar Harbor, ME). B6129F1 mice were generated in house in
our animal facility by mating 129X1SvJ females with C57BL/6
males. Recombinant Listeria monocytogenes (LM) and Salmonella
enterica serovar typhimurium (ST) expressing OVA have been
described previously [26,63]. OT-1 TCR transgenic mice
(CD45.1
+ or CD45.2
+) were bred in house. Mice were injected
first with 10
4 OT-1 cells (intravenously) and challenged several
days later intravenously with LM-OVA (10
4) or ST-OVA (10
3)i n
0.9% NaCl.
Isolation of cells from various organs
For the examination of CD8
+ T cells in various organs, mice
were first bled then anaesthetized and perfused before sacrificing
using 50 mL of PBS. Following this, organs were removed (lungs,
brain, spleen) and single cell suspensions were made. For lungs and
brain, cells were resuspended in a 40% percol solution layered
over 70% percol. After spinning, the lymphocyte fraction was
collected from the 40% fraction. Cell staining was performed as
described below.
Antigen-presentation models
Antigen-presentation was evaluated using in vitro and in vivo
models. For evaluation of antigen-presentation in vitro, a single
cell suspension of OT-1 splenocytes were seeded in a 24 well
plate at 5610
6 c e l l sp e rm lo fR P M Iw i t h8 %F B S .S o l u b l e
SIINFEKL (OVA257–264) peptide was added directly to the
culture (0.1 pg to 1 mg). Cells were allowed to proliferate for
24–72 hours and then analyzed by FACS (as described below).
In some cases OT-1 cells were first labeled with 1 mMo f
carboxyfluorescein succinimidyl ester (CFSE) for 8 minutes.
After 3–4 days of culture, cells were harvested from the wells and
stained and the expression of CFSE or other markers evaluated
by flow cytometry. For evaluation of antigen-presentation in
vivo, CFSE labeled OT-1 cells were injected (5610
6) into mice
iv. Within 3–4 days, mice were infected with various bacteria
through the iv route. Four-five days after infection, spleens were
removed from the recipient mice. The presence of donor OT-1
CD8
+ T cells (CD45.1
+) and the reduction in CFSE intensity of
donor cells was evaluated.
Figure 9. ST-OVA infection induces a lower and protracted increase in the expression of active caspase-3 consistent with delayed
and muted antigen induced CD8
+ T cell proliferation. B6129F1 mice that resist infection with ST were parked with 10
4 OT1 cells and
challenged with either 10
3 LM-OVA or 10
3 ST-OVA iv and sacrificed at various time points after infection. Single cell suspensions were obtained from
spleens and stained with various markers indicated in the figure. Relative expression of various markers on OVA-tetramer
+ CD8
+ T cells was evaluated
(A). Cells were also co-stained for DNA cleavage (TUNEL) vs. active caspase-3 expression (B). (n$3 per timepoint).
doi:10.1371/journal.pone.0015328.g009
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Antibodies were obtained from BD Biosciences (Ontario,
Canada). For surface staining, aliquots of cells (10610
6) were
incubated in 100 ml PBS plus 1% BSA (PBS-BSA) with anti-
CD16/32 at 4uC. After 10 min., cells were stained with PE-H-
2K
bOVA257–264 tetramer and various antibodies (anti-CD8, anti-
CD62L, anti-PD-1, and/or anti- IL-7Ra) for 30 min. at room
temperature. PE-H-2K
bOVA257–264 tetramer was obtained from
Beckman Coulter (Fullerton, California). Cells were washed, fixed
in 0.5% formaldehyde and acquired on BD Biosciences FACS
Canto analyzer.
For analysis of apoptosis, aliquots of cells (10610
6/ml) were
surface stained initially with anti-CD8 antibody and OVA-
tetramers as described above. This was followed by apoptotic
staining as follows. For staining with Annexin V(BD –
Cat#550474), cells were incubated with Annexin V (BD – Cat
# 556419) for 15 minutes in 3 ml Annexin binding buffer
(provided in Annexin staining kit). In order to stain cells for active
caspase-3, cells were then washed, fix/permeabilized (BD – Cat
#554714) and stained with a biotin conjugated antibody against
active caspase-3 (BD - Cat#550557), before streptavidin labeling.
In order to stain for the cleavage activity of caspase a cell-
permeable fluorogenic substrate (PhiPhiLux – OncoImmunin
Maryland, USA - Cat# A304R1G-3) was used according to the
manufacturers recommended protocol. DNA cleavage was
examined using the Apo-Direct kit (BD – Cat #556381). Briefly,
cells were stained extracellularly, then fixed using a combination
fixative/permeabilization solution (BD – Cat #554714). Cells
were then stained with a solution containing terminal transferase
enzyme and a FITC labeled dNTP. After incubation at 37uC for
1 hour cells were then fixed in 0.5% formaldehyde and read by
flow cytometry. For cell death experiments, OT-1 cells were
sometimes stimulated with 1 mg/ml of staurosporine for 6 hours to
induce apoptosis.
Figure 10. Caspase-3 is induced by antigen, not inflammation in vivo. B6129F1 mice were parked with 10
4 OT1 spleen cells, then infected
with ST-OVA or LM-OVA (10
3, iv) and sacrificed at several time points between days 4 and 60 post-infection. Splenic suspensions were analyzed for (A)
bacterial load by CFU, (B) bacterial OVA mRNA expression by qRT-PCR, and (C) the relative induction of 40 cytokines/chemokines by cytokine
proteome array (day 6). (D) CFSE labeled OT1 cells were injected into B6129F1 mice that were challenged with LM-OVA or ST-OVA, and the
proliferation and caspase 3 expression of OVA-specific evaluated at day 5 after infection. Scatter plots show data obtained from gated OVA specific
CD8
+ T cells. Data shown is representative for at least 3 mice per timepoint.
doi:10.1371/journal.pone.0015328.g010
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imaging
OT1 spleen cells were obtained from a naı ¨ve donor animal and
placed in a flask at approximately 5610
6 cells/ml. 10
4 LM-OVA
bacteria were then added to the flask and the infected culture was
incubated overnight at 37uC. At this time, cells were spun down
and washed in fresh media to remove bacteria from the culture. A
high amount of gentamicin (50 mg/ml) was also added to prevent
further bacterial replication. Cells were then returned to a flask at
2610
6 cells/ml and allowed to proliferate overnight. At 48 hours
after initial infection the cells are split to allow further proliferation
to occur; at this time supporting IL-7 is also added to the culture at
1 ng/ml. After 3 days in culture, an aliquot of cells was stained
using a similar procedure as detailed above to confirm that $90%
of cells are CD8
+ and active caspase-3
+. Cells were then counted
and placed in a 96 well round bottom flask at approximately 200
cells per well. Two fold dilutions were performed row-wise down
to approximately 6.25 cells/well. At various time intervals, TMRE
was added at 1 nM and live cells were examined using Olympus
IX81 fluorescent microscope after 18 h. At least 6 wells were
examined for every dilution of cells. 12.5 cells/well was chosen for
daily analysis because the number of cells was adequate for
counting, while providing a small enough number to preclude the
possibility that a sub-population outgrowth accounts for the
majority of the culture. Similarly, day 12 cells were examined for
viability at low cell numbers.
Cell sorting
Spleens were obtained from CD45.1
+ OT1 parked CD45.2
+
C57BL6/J recipient mice at day 5 after LM-OVA infection. CD8
+
T cells were then enriched by negative selection (Stem cell
Cat#19753) according to the manufacturer’s instructions. Cells
were stained for CD45.1 APC and caspase activity using
PhiPhiLux. Cells were then sorted on MoFlo cell sorter into
CD45.1
+ OVA-specific CD8
+ T cells that express low or high
levels of caspase 3 activity. Sorted cells were then placed in 96 well
plates with or without the addition of supporting IL-7 (1 ng/ml)
using limiting dilutions. Cells were examined for viability over
several days using TMRE staining similarly as described above.
Cell imaging
Cells were stained similarly as described for FACS analysis.
Cells were then resuspended in a small amount of Vecta Shield
and mounted on slides. Slides were then examined on Olympus
IX81 fluorescence microscope.
Proteomic analysis
Infected mouse spleens were screened using the R&D Systems
Proteome Profiler
TM Mouse Cytokine Array Panel A Array Kit as
per the manufacturer’s instructions. In brief spleen samples were
collected and homogenized in PBS containing 1% phenylmetha-
nesulphonylfluoride (PMSF) and stored at 280uC until use on the
array. Membranes were processed using the manufacturer’s
protocol and treated with Super signal West Femto chemilumi-
niscent detection reagent for 2–3 minutes. Images were captured
by a Flourochem 8900 (Alpha Innotech) imager. Spot densitom-
etry was measured using the AlphaEaseFC Software (Alpha
Innotech) and each membrane was calibrated to a positive control
standards. Values obtained from infected spleens were compared
to naı ¨ve spleens and fold changes calculated.
Quantitative RT-PCR
qRT-PCR was performed as described in detail previously
[42,64]. Expression of OVA mRNA was evaluated in LM-OVA
and ST-OVA infected spleens in vivo at various timepoints. 5–
10 mg of total RNA was taken for cDNA synthesis. After cycling, a
melting curve protocol was performed to verify that the products
had the expected melting temperature.
Statistics
For the experiments listed above statistical analysis was
performed using GraphPad Prism 5. Methods used included
Pearson correlations to test similarity in expression patterns for
many of the proteins examined. Those figures which describe
significant correlation have been confirmed to have a Pearson
r.0.95. Students T tests were also used to confirm significance of
results.
Supporting Information
Figure S1 Active caspase-3 does not correlate with
significant cell death in in vitro activated CD8
+ OT1 T-
cells. OT1 spleen cells were placed in a single cell suspension and
exposed overnight to 10
4 LM-OVA bacteria. Bacteria were then
washed from the culture and a high level of gentamicin was added
to inhibit further bacterial growth. Cells were allowed a further 2
days for CD8
+ T cells to proliferate. Cultures were then confirmed
Figure 11. Caspase-3 activation does not occur during rapid homeostatic proliferation in vivo. Rag1-/- mice were injected with 10
4 CFSE
stained OT1 cells. WT mice were injected with 10
5 CFSE stained OT1 cells concurrent with PBS, LM or LM-OVA (10
4, iv). Four days later mice were
sacrificed and spleen cell suspensions stained with anti-CD8 antibody, OVA-tetramer, followed by intracellular staining with anti-caspase-3 antibody.
Scatterplots show data obtained from gated OVA specific CD8
+ T cells and is representative of 3 mice per group.
doi:10.1371/journal.pone.0015328.g011
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+ OT1 T-cells and an aliquot was stained
for active caspase-3 (A). Cells were then placed in 96 well round-
bottom plates and diluted to 25 cells/well (B, top panels). Over
several days, cells were examined for viability using TMRE (red
colour in images) to mark metabolically active cells. Similarly, cells
at 12 days after in vitro LM-OVA activation were evaluated for
caspase-3 expression (A), and plated at 50 cells/well and examined
for viability over several days (B, bottom panels). The total number
and the number of dead cells were recorded for at least 6 replicate
wells and tracked over 72 hours in the plate (C). Histograms show
the level of active caspase-3 in day 3 and 12 in vitro activated T cells
respectively (A).
(TIF)
Figure S2 Caspase-3 activation is similar in adoptively
transferred and endogenous CD8
+ T cell response.
C57BL/6J mice were parked with 10
4 CD45.1
+ OT1 splenocytes
or no cells at all, and then both groups were challenged with 10
4
LM-OVA (iv). At days 5 and 9 post-infection, spleens were
extracted and stained with anti-CD8, OVA-tetramer, anti-
caspase-3 and, anti-Ki67 antibodies. Graphs show MFI of
CD8
+/OVA-tetramer
+ populations for expression of (A) active
caspase-3 and (B) Ki67 over time. Data shown is representative of
at least 2 mice per time-point.
(TIF)
Figure S3 Despite high caspase-3 activity, OVA-specific
CD8
+ T Cells obtained on day 4 of LM-OVA infection do
not progress to DNA fragmentation and cell death over
24 hours ex vivo. Recipient mice were parked with 10
4 OT1
splenocytes and challenged with 10
4 LM-OVA intravenously. At
day 4 post infection, cells were removed and placed ex vivo in
RPMI with 8% FBS for varying amounts of time. Apoptosis was
induced in control cells by addition of 1 mg/ml staurosporine.
Cells were then stained for (A) CD8, OVA-tetramer and active
caspase-3 or (B) CD8, OVA-tetramer and DNA fragmentation
(TUNEL). Plots show gated CD8
+ T cell populations. Data is
representative for 2 experiments.
(TIF)
Figure S4 IL-7 does not rescue apoptotic control cells,
induced using staurosporine. Spleen cells were placed in
culture at approximately 10
6 cells/well in 24 well plates. Cells were
then treated with IL-7 (1 ng/mL) and/or staurosporine. Control
cells received no treatment. After 24 hours cells were stained for
CD8
+ expression and examined for viability by exclusion of
propidium iodide.
(TIF)
Figure S5 In vitro antigenic stimulation, but not
inflammation, drives coordinated upregulation of cell
cycling and caspase-3 activation. OT-1 cells were placed in
culture and either stimulated 1 mg/ml of SIINFEKL peptide or
left unstimulated. Additional inflammatory stimulation was added
to some cultures by adding (A) 10
4 heat killed Listeria monocytogenes
(HK-LM) or (B) 10
6 heat killed Salmonella typhimurium. Scatter-
plots show the expression of caspase-3 versus Ki67 in gated CD8
+
T cells.
(TIF)
Figure S6 The specific inhibition of caspase-3 results in
a significant reduction in the proliferation of CD8
+ T
cells in response to antigenic stimulation. 10
5 CFSE
stained OT1 cells were stimulated in vitro with OVA peptide in
the presence or absence of 50 mM caspase-3 inhibitor (z-DQMD-
FMK) and examined for proliferation after 48 hours. There is a
significant decrease in proliferation induced by OVA peptide in
the presence of caspase-3 inhibitor (* P,0.05).
(TIF)
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